These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. TNF-alpha neutralization in cytokine-driven diseases: a mathematical model to account for therapeutic success in rheumatoid arthritis but therapeutic failure in systemic inflammatory response syndrome. Jit M; Henderson B; Stevens M; Seymour RM Rheumatology (Oxford); 2005 Mar; 44(3):323-31. PubMed ID: 15585509 [TBL] [Abstract][Full Text] [Related]
23. Enhanced Fc-dependent cellular cytotoxicity of Fc fusion proteins derived from TNF receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides. Shoji-Hosaka E; Kobayashi Y; Wakitani M; Uchida K; Niwa R; Nakamura K; Shitara K J Biochem; 2006 Dec; 140(6):777-83. PubMed ID: 17038352 [TBL] [Abstract][Full Text] [Related]
24. Etanercept - TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers? Marotte H; Cimaz R Expert Opin Biol Ther; 2014 May; 14(5):569-72. PubMed ID: 24611432 [TBL] [Abstract][Full Text] [Related]
25. Tumor necrosis factor (TNF)-soluble high-affinity receptor complex as a TNF antagonist. McKenna SD; Feger G; Kelton C; Yang M; Ardissone V; Cirillo R; Vitte PA; Jiang X; Campbell RK J Pharmacol Exp Ther; 2007 Aug; 322(2):822-8. PubMed ID: 17495128 [TBL] [Abstract][Full Text] [Related]
26. Natural form of noncytolytic flexible human Fc as a long-acting carrier of agonistic ligand, erythropoietin. Im SJ; Yang SI; Yang SH; Choi DH; Choi SY; Kim HS; Jang DS; Jin KS; Chung YK; Kim SH; Paik SH; Park YC; Chung MK; Kim YB; Han KH; Choi KY; Sung YC PLoS One; 2011; 6(9):e24574. PubMed ID: 21957455 [TBL] [Abstract][Full Text] [Related]
27. CD200-Fc, a novel antiarthritic biologic agent that targets proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis. Simelyte E; Criado G; Essex D; Uger RA; Feldmann M; Williams RO Arthritis Rheum; 2008 Apr; 58(4):1038-43. PubMed ID: 18383359 [TBL] [Abstract][Full Text] [Related]
34. Neutralization of ocular surface TNF-α reduces ocular surface and lacrimal gland inflammation induced by in vivo dry eye. Ji YW; Byun YJ; Choi W; Jeong E; Kim JS; Noh H; Kim ES; Song YJ; Park SK; Lee HK Invest Ophthalmol Vis Sci; 2013 Nov; 54(12):7557-66. PubMed ID: 24052636 [TBL] [Abstract][Full Text] [Related]
35. Binding and functional comparisons of two types of tumor necrosis factor antagonists. Scallon B; Cai A; Solowski N; Rosenberg A; Song XY; Shealy D; Wagner C J Pharmacol Exp Ther; 2002 May; 301(2):418-26. PubMed ID: 11961039 [TBL] [Abstract][Full Text] [Related]
36. Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis. Murray KM; Dahl SL Ann Pharmacother; 1997 Nov; 31(11):1335-8. PubMed ID: 9391689 [TBL] [Abstract][Full Text] [Related]
37. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Coppieters K; Dreier T; Silence K; de Haard H; Lauwereys M; Casteels P; Beirnaert E; Jonckheere H; Van de Wiele C; Staelens L; Hostens J; Revets H; Remaut E; Elewaut D; Rottiers P Arthritis Rheum; 2006 Jun; 54(6):1856-66. PubMed ID: 16736523 [TBL] [Abstract][Full Text] [Related]
38. Etanercept for the treatment of psoriasis: combination therapy with other modalities. Strober BE; Clarke S J Drugs Dermatol; 2004; 3(3):270-2. PubMed ID: 15176161 [TBL] [Abstract][Full Text] [Related]
39. Hinge-Deficient IgG1 Fc Fusion: Application to Human Lactoferrin. Shiga Y; Murata D; Sugimoto A; Oshima Y; Tada M; Ishii-Watabe A; Imai K; Tomii K; Takeuchi T; Kagaya S; Sato A Mol Pharm; 2017 Sep; 14(9):3025-3035. PubMed ID: 28763236 [TBL] [Abstract][Full Text] [Related]